ライフサイエンスコーパス: mortality

1 variables nor PaO2/FIO2 were associated with mortality.

2 ocused on the resuscitation bundle on 90-day mortality.

3 for important patient-centered outcomes like mortality.

4 ovel risk factor for ILD hospitalization and mortality.

5 dependent risk factors for all-cause and CVD mortality.

6 s, causing high morbidity and, occasionally, mortality.

7 core and the primary outcome was in-hospital mortality.

8 ukin-6 (IL-6) levels, bacteremia, and sepsis mortality.

9 ialysis, hospital readmission, and long-term mortality.

10 DAMTS13 IgG antibody and ADAMTS13 antigen on mortality.

11 States and a leading cause of morbidity and mortality.

12 subclassification, hemodynamic profiles, and mortality.

13 ion/ sepsis is the leading cause of mid-term mortality.

14 dy period, in-hospital mortality, and 1-year mortality.

15 In-hospital mortality.

16 blood pressure, systemic arterial load, and mortality.

17 te the decline in tuberculosis incidence and mortality.

18 The primary outcome was all-cause mortality.

19 significant effect on disease morbidity and mortality.

20 n between residential radon and brain cancer mortality.

21 decreased risk of death from CRC and overall mortality.

22 trial-esophageal fistula (AEF) and increased mortality.

23 or coronary heart disease and cardiovascular mortality.

24 fections result in significant morbidity and mortality.

25 etion of the 3-hour bundle and risk-adjusted mortality.

26 cPC22A virus caused severe diarrhea and 100% mortality.

27 o climate change caused by changes in forest mortality.

28 ce the greatest risk of asthma morbidity and mortality.

29 ospital stay, increased cost and substantial mortality.

30 of the subsequent increase in morbidity and mortality.

31 al feeding of two different dsRNAs increased mortality.

32 o evaluate the effect of infection status on mortality.

33 ncer, breast cancers still cause significant mortality.

34 s and tumor recurrence, resulting in patient mortality.

35 8 mortality, and 3) ICU discharge and 1-year mortality.

36 ationship to control of parasitemia and host mortality.

37 association with S. aureus bacteremia (SaB) mortality.

38 of these countries, falls in overall suicide mortality.

39 th sarcopenia presented the greatest risk of mortality.

40 ents has been associated with a reduction in mortality.

41 r cirrhosis lead to a dramatically increased mortality.

42 hium may reduce melanoma risk and associated mortality.

43 ADA HbA1c clinical categories for all-cause mortality.

44 UC + PAL did not affect rehospitalization or mortality.

45 Hospital mortality (2.5% in the intensive group vs 4.9% in the mo

46 (27.5%), maternal mortality (4%), and fetal mortality (2.5%).

47 rkers measured on 1) ICU admission and day 4 mortality, 2) day 4 and day 28 mortality, and 3) ICU dis

48 ission (22.4% vs 21.7%; P > .99), and 90-day mortality (3.3% vs 1.3%; P = .38).

49 In-hospital mortality, 30-day mortality, and 1-year mortality after

50 nary artery bypass surgery (27.5%), maternal mortality (4%), and fetal mortality (2.5%).

51 f ventilation, intensive care unit stay, and mortality (6, 17, and 29% for the three groups, respecti

52 rs had a significantly higher risk of 30-day mortality (898 [6.5%] vs 790 [5.8%]; % absolute RD, 0.79

53 al and observational data of drought-induced mortality across the Neotropics to the large-scale biocl

54 oxifloxacin or levofloxacin) use and patient mortality, adjusting for risk factors typically associat

55 The CI of nonrelapse mortality after 1 year was 17% (95% CI, 8% to 26%) after

56 Mortality after AKI is high, but the causes of death are

57 use was not associated with cancer-specific mortality after diagnosis of esophageal cancer (pooled a

58 ital mortality, 30-day mortality, and 1-year mortality after TAVR in patients with and without DM wer

59 ncy and trends in the residual burden of HIV mortality after the roll-out of a public sector ART prog

60 s mellitus (DM) is associated with increased mortality after transplantation, but the effect of glyce

61 In separate analyses of +MWF and -MWF, total mortality (aHR: 0.23; 95% CI: 0.07 to 0.75), total morta

62 en associated with reduced VT recurrence and mortality, although it is typically not considered among

63 nor, was associated with increased all-cause mortality among male recipients but not among female rec

64 in antibiotic administration and in-hospital mortality among patient encounters with community-acquir

65 ncluded in the analyses ranged from 1364 for mortality among patients admitted for acute myocardial i

66 for acute myocardial infarction to 2615 for mortality among patients admitted for pneumonia) and con

67 The long-term mortality among patients with undiagnosed diabetes melli

68 The mortality among persons with Parkinson disease is only m

69 mortality was substantially lower than male mortality among the oldest-old, but that women's functio

70 ated with poor outcomes, including increased mortality, among critically ill children and young adult

71 or all-cause mortality, nor in total cancer mortality, among those taking aspirin.

72 ed with increased longer-term cardiovascular mortality and (2) incremental prognostic use of indexing

73 decade after donation, the risk of all-cause mortality and cardiovascular events is no higher than in

74 There is still a high rate of short-term mortality and complications in acute coronary syndrome p

75 a is associated with increased morbidity and mortality and different patterns of LV remodeling and re

76 her the relationship between drought-induced mortality and distributions holds continentally by relat

77 d is independently associated with increased mortality and greater disability.

78 Hg) decreased MACE, including cardiovascular mortality and heart failure.

79 pressure values was consistent with reduced mortality and increased proportions of patients with goo

80 is a common and independent risk factor for mortality and longer hospital stay.

81 0% is a significant independent predictor of mortality and may aid in sepsis care.

82 inority race or ethnicity is associated with mortality and mediated by health insurance coverage amon

83 Perinatal mortality and morbidity continue to be major global heal

84 compared with even fluid balance, on 1-year mortality and renal recovery.

85 x performed better in distinguishing between mortality and survival (the area under the receiver oper

86 r air quality, was associated with increased mortality and that associations vary by urbanicity and c

87 urgently needed to significantly reduce both mortality and the healthcare costs associated with bacte

88 30 and 90 days were </=1.0% and </=4.6% for mortality, and </=40.8 and </=42.8 for the comprehensive

89 In-hospital mortality, 30-day mortality, and 1-year mortality after TAVR in patients w

90 cidence during the study period, in-hospital mortality, and 1-year mortality.

91 ion and day 4 mortality, 2) day 4 and day 28 mortality, and 3) ICU discharge and 1-year mortality.

92 in use decreased the risk of decompensation, mortality, and HCC in a dose-dependent manner (P for tre

93 AKI is associated with high morbidity and mortality, and it predisposes to the development and pro

94 improved perioperative outcomes, short-term mortality, and overall survival.

95 basis for the primary outcome of in-hospital mortality, and secondary outcomes including 30-day morta

96 on global and regional trends in incidence, mortality, and survival, and the consequences, especiall

97 the main reason for breast cancer-associated mortality, and there are unmet clinical demands for the

98 The association between heat waves and mortality appeared acutely and lasted for 3 and 4 d.

99 , retrograde type A dissection and follow-up mortality appeared lower.

100 cular disease, although cancer incidence and mortality are also increased.

101 presence and form of the social relationship/mortality association in a representative sample of US B

102 adenoviral infections and transplant-related mortality at 1 year were 4.2% +/- 4.1%, 58.8% +/- 9.8%,

103 Primary outcome was mortality at 28-days.

104 zard ratio for acute rejection and all-cause mortality at 3 years in recipients who have experienced

105 The primary endpoint was all-cause mortality at 30 days.

106 ril 2009 and March 2014 to compare perinatal mortality between induction of labour at 39, 40, and 41

107 e death, cardiovascular death, and all-cause mortality by 28% (P=0.020), 25% (P=0.009), and 18% (P=0.

108 nfidence intervals (CIs) for cancer-specific mortality by low-dose aspirin use after adjusting for po

109 We aimed to assess mortality by occupation in the UK, differences in rates

110 Ripk3(-/-) mice exhibited enhanced mortality compared to wild-type (WT) controls, while mic

111 ficant organ protection and markedly reduced mortality compared with nontreated controls (four of fiv

112 therapies for neovascular AMD had decreased mortality compared with those who did not (HR, 0.71; 95%

113 Morbidity and mortality conference is a common educational and quality

114 care, hospitalization, disease registry, and mortality data in England.

115 th recording or contain misclassification of mortality data.

116 linked by Statistics Canada to the Canadian mortality database and to annual income tax filings thro

117 Factors associated with mortality differences between early goal-directed therap

118 er the entire dose range, there are negative mortality dose trends for all circulatory disease (p = 0

119 y become an important cause of morbidity and mortality due to healthcare-associated infections.

120 nt residences were associated with increased mortality during TB treatment, although the findings wer

121 t less likely to suffer severe morbidity and mortality during the 2009 influenza pandemic.

122 f adaptive immune defects, strongly predicts mortality during treated human immunodeficiency virus (H

123 Mortality fell from the initial registry to the subseque

124 Mortality follow-up extended up to 18 months after this

125 Multivariate predictors of mortality following HCC recurrence were identified to de

126 Multivariate predictors of mortality following recurrence included model for end-st

127 We projected excess mortality for cold and heat and their net change in 1990

128 In-hospital mortality for females declined from 61.0% in 2002 to 49.

129 between residential radon with brain cancer mortality for males and females and the intensity of the

130 to 49.0% in 2014 (P for trend <0.001), while mortality for males declined from 48.6% in 2002 to 32.2%

131 cohort of patients on dialysis revealed that mortality from acute myocardial infarction (AMI) has dec

132 angling the relative importance of host tree mortality from changes in soil chemistry following tree

133 Bycatch mortality from fisheries is clearly among the most serio

134 ocioeconomic status and increasing burden of mortality from non-communicable diseases is likely to be

135 Bycatch mortality has high population-level impacts in all three

136 han 85% transplant was associated with lower mortality hazard after the first year compared with the

137 ce and young adulthood coincide with greater mortality hazard and greater chances of nonadherence to

138 e medication after HTx, but the elevation of mortality hazard in this age range persists in the absen

139 RBCs ratios were not associated with 30-day mortality hazard ratios after controlling for baseline c

140 th a partial nephrectomy had reduced risk of mortality (hazard ratio, 0.55; 95% CI, 0.49 to 0.62).

141 Disease progression includes composite mortality, hospitalization, and 10% FVC decline.

142 omas reduces colorectal cancer incidence and mortality; however, the benefit of surveillance colonosc

143 ined endpoint of HF readmission or all-cause mortality (HR: 0.90; 95% CI: 0.84 to 0.96; p = 0.002), b

144 associated with a similar risk of all-cause mortality (HR: 1.14; 95% CI: 0.99 to 1.32), but higher r

145 positively associated with colorectal cancer mortality [HR per 6.5 ppb=1.06 (95% CI: 1.02, 1.10).

146 ll graft loss [HR, 1.08; 95% CI, 0.91-1.28]; mortality [HR, 0.84; 95% CI, 0.67-1.06]).

147 syndrome (AIDS)-related (NLR-NAR) events and mortality in a cohort of human immunodeficiency virus (H

148 values collected at follow-up with all-cause mortality in a prospective and consecutive cohort of pat

149 SOFA may have limited utility for predicting mortality in an ICU setting.

150 Mortality in cardiogenic shock (CS) remains high.

151 se of CPAP did not decrease all-cause 2-week mortality in children 1 month to 5 years of age with und

152 The leading cause of mortality in HFpEF is sudden death, but little is known

153 acteria that cause significant morbidity and mortality in humans worldwide.

154 mong the top ten causes of infection-related mortality in humans.

155 respiratory virus that causes morbidity and mortality in humans.

156 n-based therapies in reducing cardiovascular mortality in individuals with CKD seems to diminish as e

157 We found an increased long-term mortality in individuals with wet AMD treated with bevac

158 , biologic, and clinical risk factors to RSV mortality in low-income regions is unclear.

159 zation by two bacterial pathogens that cause mortality in neonates.

160 nza viral infections often lead to increased mortality in older people.

161 4(+)/VEGF(+)) were independent predictors of mortality in patients with HF with preserved ejection fr

162 e-guided HF management reduces morbidity and mortality in patients with HFrEF on GDMT, underscoring t

163 inical practice and strongly correlated with mortality in patients with infarct-related CS.

164 ibitor, reduced cardiovascular morbidity and mortality in patients with type 2 diabetes mellitus and

165 erate ARDS, and the possibility of decreased mortality in patients with very severe ARDS.

166 imum management of comorbidities in reducing mortality in people with HIV.

167 .846; 95% CI: 0.796-0.899) reduction in ACSC mortality in the black/pardo group compared with a 6.8%

168 All-cause mortality in the entire Medicare population from 2000 to

169 ted tomography are associated with all-cause mortality in the general population.

170 Long-term mortality in the propensity score-matched populations wa

171 retic therapy did not reduce 28-day/hospital mortality in the randomized studies (relative risk, 0.93

172 ections are a leading cause of morbidity and mortality in the United States and are associated with i

173 important clinical outcomes associated with mortality in this injury process.

174 ity, and secondary outcomes including 30-day mortality, in-hospital and 30-day death/stroke, procedur

175 Independent predictors of mortality included cardiac variables (New York Heart Ass

176 During this period, tree mortality increased by an order of magnitude, typically

177 m (2000-2014) who underwent a subset of high-mortality inpatient general, vascular, or thoracic proce

178 ll, the association between dairy intake and mortality is inconclusive.We studied associations betwee

179 Among patients with SHFM-predicted annual mortality </=5.7%, those with a SPRM-predicted risk of s

180 statistically significantly lower all-cause mortality (men: HR, 0.88 [95% CI, 0.82 to 0.95]; P for t

181 the increasing impact of cancer on worldwide mortality, more and more attention is being devoted to t

182 The primary outcome was all-cause mortality; myocardial infarction, revascularization, and

183 f stillbirth or neonatal, 6-month, or infant mortality, neither overall or in any of the 26 examined

184 s in the two arms were not the same, neither mortality nor clinical efficacy was reported, only pharm

185 rdiovascular disease mortality, or all-cause mortality, nor in total cancer mortality, among those ta

186 A continued excess mortality occurred after perforation, with an odds ratio

187 95% CI, 1.90-2.51) but no increased odds of mortality (odd ratio, 1.07; 95% CI, .67-1.71).

188 ciated with higher risk-adjusted in-hospital mortality (odds ratio, 1.04 per hour; 95% confidence int

189 ity, 1.04; 95% CI, 1.02-1.06; p < 0.001) and mortality (odds ratio, 1.06; 95% CI, 1.04-1.08; p < 0.00

190 perforation, with an odds ratio for 12-month mortality of 1.35 for perforation survivors compared wit

191 The mortality of AMA-positive patients without PBC is increa

192 among subgroups related to the incidence and mortality of these cancers exist.

193 ity (aHR: 0.23; 95% CI: 0.07 to 0.75), total mortality or heart failure hospitalization (aHR: 0.32; 9

194 (aHR: 0.32; 95% CI: 0.12 to 0.82), and total mortality or hospitalization for major adverse cardiac e

195 patients with heart failure does not reduce mortality or hospitalizations, less is known about its e

196 Secondary outcomes included a composite of mortality or other medical complications (myocardial inf

197 outcome (HF hospitalization, cardiovascular mortality, or aborted cardiac arrest), its components, a

198 e in nonfatal stroke, cardiovascular disease mortality, or all-cause mortality, nor in total cancer m

199 PC1&PC2 independently predicted 90-day mortality (ORs 2.6, 95%CI = 1.3-6.4; and 2.4, 95%CI = 1.

200 was independently associated with increased mortality (P = 0.003; odds ratio, 1.254; 95% confidence

201 elapse (>/=30 g/day) was not associated with mortality (P = 0.24) during the short-term period (1,606

202 een associated with increasing postoperative mortality (POM).

203 primary outcomes of interest were perinatal mortality, preterm birth, hospital attendance for asthma

204 ease in NE and significant increased risk of mortality provides evidence that GBS infection contribut

205 engthen the evidence for circulatory-disease mortality radiation risk at doses <0.5 Gy.

206 The annualized mortality rate after a bleeding event was 21.5 (95% CI,

207 Primary outcome was 30-day mortality rate for all hospitalizations and for 15 commo

208 We estimated that the under-5 mortality rate in PMI countries was reduced from 28.9 to

209 Treatment was well tolerated, with a 6-week mortality rate of 0%.

210 A reduced 14-day mortality rate was observed in the molecular adsorbent r

211 ICU in Australia and New Zealand have a high mortality rate.

212 ased on preimplementation trends) and actual mortality rates (hospital mean of 6.48 deaths per 1000 a

213 We compared postoperative mortality rates after inpatient surgery in South Carolin

214 no significant differences in overall 30-day mortality rates among patients treated by locum tenens c

215 Plant mortality rates and biomass declines in response to drou

216 ated biting rates to be largest and mosquito mortality rates and extrinsic incubation periods to be s

217 an urgent need to rigorously estimate actual mortality rates and quantify effects of bycatch on popul

218 nti-inflammatory cytokines would have higher mortality rates and that these biomarkers could improve

219 ngly associated with higher working-age male mortality rates both between 1992 and 1998 (age-standard

220 nvironmental factors in regulating birth and mortality rates can lead to erroneous demographic analys

221 Blacks and Hispanics had similar mortality rates compared with whites (adjusted hazard ra

222 for all racial/ethnic groups increased, and mortality rates decreased by 5-7% annually.

223 ly in Nigeria, leading to high morbidity and mortality rates for children <5 years of age.

224 Adjusted mortality rates slightly declined over the study period.

225 n prenatal smoking and NEC-associated infant mortality rates with adjustment for potential confounder

226 We aimed to determine whether higher mortality rates with high milk consumption are modified

227 n uncommon situation with high morbidity and mortality rates, and delayed small bowel perforation is

228 ates (<2500 g at inclusion) to reduce infant mortality rates, we observed a very beneficial effect in

229 ng the highest extinction risk under current mortality rates.

230 est influenza-associated hospitalization and mortality rates.

231 both between 1992 and 1998 (age-standardised mortality ratio in men aged 20-69 years in fast vs slow

232 We used standardised mortality ratios (SMRs) to make comparisons with the gen

233 atios for 1-year adverse outcomes, including mortality, readmission, and bleeding, for patients with

234 ES) and Office for National Statistics (ONS) mortality records.

235 nce and partial canopy dieback to whole-tree mortality reduce canopy leaf area during the stress peri

236 g-term benefits (e.g., life-years gained and mortality reduction) and harms (e.g., overdiagnosis) of

237 to estimate the community-specific heat wave-mortality relation over lags of 0-10 d.

238 of even the youngest children, morbidity and mortality remain higher with chronic dialysis than after

239 The hazard of mortality remained, but decreased 14% per year for DDKT

240 PTC, but its prognostic value in PTC-related mortality remains to be specifically established.

241 Overall mortality/repeat LTx was 31%.

242 environmental tolerances related to growth, mortality, reproduction, disturbances, and biotic intera

243 e those for major complications, in-hospital mortality, retrograde type A dissection and follow-up mo

244 lem that implicates inequities and extrinsic mortality risk - documenting more future-oriented thinki

245 splantation (HTx) recipients experience high mortality risk attributed to increased nonadherence to i

246 The role of extrinsic mortality risk in driving behaviour is probably importan

247 Annual mortality risk per thousand tons of precursor emissions

248 46% of mortality risk was explained by multivariable modelling

249 Excess mortality risk was found for concordant causes of death

250 idea using the specific factor of extrinsic mortality risk, an important factor in evolutionary theo

251 rail recipients may be a marker of increased mortality risk.

252 rmed HLA DSA is associated with an increased mortality risk.

253 grip strength (GS) is associated with lower mortality risk.

254 nt knowledge of ARDS trends in incidence and mortality, risk factors, and recently described endotype

255 e had increased all-cause and cardiovascular mortality risks (log rank P=0.004 and P=0.003, respectiv

256 The predicted prestage 1 and 2 mortality risks were calculated for each patient.

257 nt RCTs and calculated pooled OR for 3-month mortality (safety outcome) and 3-month death or dependen

258 ciety of Thoracic Surgeons Predicted Risk of Mortality score for decision making and assessment of ea

259 uses of death to global influenza-associated mortality should be investigated.

260 f less than 150 mm Hg to reduce the risk for mortality, stroke, and cardiac events.

261 review the methodology employed in surgical mortality studies to control for potential confounders.

262 its incidence, treatment, and event-related mortality, thereby addressing an important unmet clinica

263 pplied this approach to project age-specific mortality to 2030 in 35 industrialised countries with hi

264 n done on systemic lupus erythematosus (SLE) mortality trends in the United States.

265 The primary outcome was all-cause mortality until 28 days.

266 We examined all-cause mortality using adjusted Cox models.

267 In-hospital mortality using clinical criteria declined (-3.3%/y [95%

268 ociations between R/S and incident all-cause mortality using proportional hazards models.

269 In 2013, age-adjusted TBI mortality was 12.99 per 100,000 population (SE = 0.13).

270 Overall 30-day mortality was 17.6%.

271 Overall in-hospital mortality was 17.8% (55 patients): 227 patients (73.5%)

272 hospitalizations where 180-day postdischarge mortality was 50%, a prognostic bench mark for hospice r

273 n failure occurred in 15.2%, and in-hospital mortality was 6.5%.

274 p < 0.001) and varied by type of CNS injury; mortality was 79.6% in patients with intracranial hemorr

275 Hospital mortality was 86.6% and 95.9%, respectively.

276 Risk of all-cause and cause-specific mortality was assessed with Cox proportional hazards mod

277 Among HIV-uninfected patients, mortality was associated with higher CSF neutrophil coun

278 Thirty-day mortality was comparable among patients with PMI not ful

279 ecified secondary analysis, no difference in mortality was found (odds ratio, 1.16; 95% CI, 0.89-1.50

280 Evaluation tool, the quality of evidence for mortality was high.

281 All-cause mortality was higher for nonadherent patients (hazard ra

282 Hospital mortality was lowest among patients with severe sepsis w

283 ermented milk intake and increased all-cause mortality was recently reported, but overall, the associ

284 In-hospital mortality was significantly higher for those with CNS co

285 Cohort mortality was significantly higher than the general popu

286 Hospital mortality was similar (12.4% vs 10.3%; p = 0.635).

287 The risk of 3-month mortality was similar between patients randomised to int

288 We also noted that female mortality was substantially lower than male mortality am

289 All-cause mortality was the primary endpoint.

290 9, respectively, and the unadjusted rates of mortality were 60.2 versus 40.4, respectively.

291 of critical care intervention and inhospital mortality were determined.

292 95% CIs for colorectal cancer incidence and mortality were estimated for intention-to-treat and per-

293 a coronary revascularization procedure), and mortality were identified from 1 year after hospital dis

294 ge of concentrations, and immobilization and mortality were monitored.

295 riable analyses, the odds of major morbidity/mortality were similar for early-career (<15 years from

296 We examined differences in mortality when ICU patients were admitted under intensiv

297 rhea, lower titers of viral shedding, and no mortality, whereas the icPC22A virus caused severe diarr

298 tween intake of dairy products and all-cause mortality with an emphasis on nonfermented milk and fat

299 n death below the median had no reduction in mortality with the ICD (adjusted ICD HR: 0.921; 95% CI:

300 rdiac arrest), its components, and all-cause mortality with the use of multivariable Cox models.

301 for preventing breast cancer recurrence and mortality, yet data from prospective cohort studies are